Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Expertise in Mesothelioma: HELP
Chikao Morimoto
Based on 16 articles published since 2008
||||
Expertise Level
The expertise of Chikao Morimoto ranks in the
  • Top 2.2%
  • ... of 16,577 published authors worldwide on Mesothelioma
  • ... from 2008 through 2019
  • ... based on contributions to 16 articles on the topic.
Graphical view (beta)
Uncounted papers?
Aliases Morimoto, C   ·   Morimoto, Chikao
Work Locations
Details
Most likely:    University of Tokyo      
2018
  • Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan. · Department of Pathology, Saitama Medical University, Saitama, Japan. · Y's AC Company, Tokyo, Japan. · Biological Research Institute, CA, USA. · Division of Hematology/Oncology, University of Florida Shands Cancer Center, Gainesville, FL, USA. · Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan. Electronic address: · Pubmed 30197002
2017
  • Gustave Roussy, Université Paris-Saclay, Drug Development Department (DITEP), Villejuif, France. · Centre Georges-François Leclerc, Unité de Phases Précoces, Dijon, France. · Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Lyon, France. · Hôpital Cochin, Paris, France. · Centre Hospitalier Universitaire (CHU) de Caen, Centre de Recherche Clinique/Essais de phases précoces, Caen, France. · Gustave Roussy, Translational Research Laboratory, Villejuif, France. · FV Clinical subcontractor for SynteractHCR SAS, Levallois-Perret, France. · Y's therapeutics Inc., Redwood City, CA, USA. · Kissei Pharmaceutical Co., Ltd, Tokyo, Japan. · Department of Rheumatology and Allergy, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. · Division of Hematology/Oncology, University of Florida, Gainesville, FL, USA. · Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan. · Keio University School of Medicine, Tokyo, Japan. · Saitama Medical University, Saitama, Japan. · Y's AC Co., Ltd, Tokyo, Japan. · Pubmed 28291776
2016
  • Department of Pathology, Kyorin University School of Medicine, 6-20-2, Shinkawa, Mitaka-shi, Tokyo, 181-8611, Japan. · Departments of Pathology and Oncology, Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. · Departments of Pathology and Oncology, Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. · Department of Pathology, Tokyo Medical University Hachioji Medical Center, 1163 Tatemachi, Hachioji-shi, Tokyo, 193-0998, Japan. · Therapy Development and Innovation for Immune Disorders and Cancers, Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. · Pubmed 27342200
2014
  • Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Japan. · Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Hongo, Bunkyo-ku, Tokyo, Japan. · Department of Medical Oncology and Clinical Research, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, Yamaguchi, Japan. · Department of Pathology, Keio University school of Medicine, Tokyo, Japan. · Department of Internal Medicine, Okayama Rosai Hospital, Okayama, Japan. · Pubmed 25526639
  • Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. · Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. Electronic address: · Division of Hematology/Oncology, University of Florida, 1600 SW Archer Road, Box 100278, Room MSB M410A, Gainesville, FL 32610, USA. · Department of Pathology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. · Pubmed 24747072
  • Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. · Division of Hematology/Oncology, University of Florida, 1600 SW Archer Road, Box 100278, Room MSB M410A, Gainesville, FL 32610, USA. · Department of Medical Oncology and Clinical Research, National Hospital Organization Yamaguchi-Ube Medical Center, 685 Higashi-Kiwa, Ube, Yamaguchi 755-0241, Japan. · Department of Respiratory Medicine, Okayama Rosai Hospital, 1-10-25 Chikkomidorimachi, Okayama Minami-ku, Okayama 702-8055, Japan. · Department of Pathology, Keio University School of Medicine, 35 Shinanomachi Shinjuku-ku, Tokyo 160-8582, Japan. · Pubmed 24743707
  • Department of Therapy Development and Innovation for Immune disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan ; Division of Clinical Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan. · Department of Therapy Development and Innovation for Immune disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan. · Division of Hematology and Oncology, University of Florida Shands Cancer Center, Gainesville, Florida, United States of America. · Pubmed 24466195
2013
  • Department of Pathology, School of Medicine, Keio University, Shinjuku-ku, Tokyo, Japan. · Pubmed 23638030
2012
  • Division of Clinical Immunology, Institute of Medical Science, University of Tokyo, Japan. · Pubmed 22369943
2011
  • Division of Clinical Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan. · Pubmed 21163253
Probable:    Juntendo University      
2018
  • Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan. · Department of Pathology, Saitama Medical University, Saitama, Japan. · Y's AC Company, Tokyo, Japan. · Biological Research Institute, CA, USA. · Division of Hematology/Oncology, University of Florida Shands Cancer Center, Gainesville, FL, USA. · Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan. Electronic address: · Pubmed 30197002
2017
  • Gustave Roussy, Université Paris-Saclay, Drug Development Department (DITEP), Villejuif, France. · Centre Georges-François Leclerc, Unité de Phases Précoces, Dijon, France. · Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Lyon, France. · Hôpital Cochin, Paris, France. · Centre Hospitalier Universitaire (CHU) de Caen, Centre de Recherche Clinique/Essais de phases précoces, Caen, France. · Gustave Roussy, Translational Research Laboratory, Villejuif, France. · FV Clinical subcontractor for SynteractHCR SAS, Levallois-Perret, France. · Y's therapeutics Inc., Redwood City, CA, USA. · Kissei Pharmaceutical Co., Ltd, Tokyo, Japan. · Department of Rheumatology and Allergy, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. · Division of Hematology/Oncology, University of Florida, Gainesville, FL, USA. · Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan. · Keio University School of Medicine, Tokyo, Japan. · Saitama Medical University, Saitama, Japan. · Y's AC Co., Ltd, Tokyo, Japan. · Pubmed 28291776
2016
  • Dept. of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University. · Pubmed 27431629
  • Department of Pathology, Kyorin University School of Medicine, 6-20-2, Shinkawa, Mitaka-shi, Tokyo, 181-8611, Japan. · Departments of Pathology and Oncology, Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. · Departments of Pathology and Oncology, Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. · Department of Pathology, Tokyo Medical University Hachioji Medical Center, 1163 Tatemachi, Hachioji-shi, Tokyo, 193-0998, Japan. · Therapy Development and Innovation for Immune Disorders and Cancers, Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. · Pubmed 27342200
2014
  • Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Japan. · Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Hongo, Bunkyo-ku, Tokyo, Japan. · Department of Medical Oncology and Clinical Research, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, Yamaguchi, Japan. · Department of Pathology, Keio University school of Medicine, Tokyo, Japan. · Department of Internal Medicine, Okayama Rosai Hospital, Okayama, Japan. · Pubmed 25526639
  • Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. · Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. Electronic address: · Division of Hematology/Oncology, University of Florida, 1600 SW Archer Road, Box 100278, Room MSB M410A, Gainesville, FL 32610, USA. · Department of Pathology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. · Pubmed 24747072
  • Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. · Division of Hematology/Oncology, University of Florida, 1600 SW Archer Road, Box 100278, Room MSB M410A, Gainesville, FL 32610, USA. · Department of Medical Oncology and Clinical Research, National Hospital Organization Yamaguchi-Ube Medical Center, 685 Higashi-Kiwa, Ube, Yamaguchi 755-0241, Japan. · Department of Respiratory Medicine, Okayama Rosai Hospital, 1-10-25 Chikkomidorimachi, Okayama Minami-ku, Okayama 702-8055, Japan. · Department of Pathology, Keio University School of Medicine, 35 Shinanomachi Shinjuku-ku, Tokyo 160-8582, Japan. · Pubmed 24743707
  • Department of Therapy Development and Innovation for Immune disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan ; Division of Clinical Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan. · Department of Therapy Development and Innovation for Immune disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan. · Division of Hematology and Oncology, University of Florida Shands Cancer Center, Gainesville, Florida, United States of America. · Pubmed 24466195
2012
  • Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University. · Pubmed 23259393
Show More
Specific Interests

In the titles of their published articles, experts often reveal their very specific interests.

Here are the titles of the 10 most recent articles (out of 16 total) written by Chikao Morimoto about Mesothelioma:

  • Targeting CD26 suppresses proliferation of malignant mesothelioma cell via downmodulation of ubiquitin-specific protease 22. 2018
  • First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers. 2017
  • [Development of New Therapy for Malignant Mesothelioma Based on CD26 Molecule]. 2016
  • Establishment of anti-mesothelioma monoclonal antibodies. 2016
  • Clinical significance of soluble CD26 in malignant pleural mesothelioma. 2014
  • CD26-mediated regulation of periostin expression contributes to migration and invasion of malignant pleural mesothelioma cells. 2014
  • Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma. 2014
  • CD9 negatively regulates CD26 expression and inhibits CD26-mediated enhancement of invasive potential of malignant mesothelioma cells. 2014
  • Nuclear localization of CD26 induced by a humanized monoclonal antibody inhibits tumor cell growth by modulating of POLR2A transcription. 2013
  • CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma. 2013
Show List of Full Article Records
Google Searches

Learn more about Chikao Morimoto using the ready-made Google searches below.
This is essential! -- Publications never tell the whole story!

General Search:
University of Tokyo
Juntendo University
Affiliation Timeline
Click for institutional directory in table below. (Not always available.)
What is this?
University of Tokyo
2018
  • Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan. · Department of Pathology, Saitama Medical University, Saitama, Japan. · Y's AC Company, Tokyo, Japan. · Biological Research Institute, CA, USA. · Division of Hematology/Oncology, University of Florida Shands Cancer Center, Gainesville, FL, USA. · Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan. Electronic address: · Pubmed 30197002
2017
  • Gustave Roussy, Université Paris-Saclay, Drug Development Department (DITEP), Villejuif, France. · Centre Georges-François Leclerc, Unité de Phases Précoces, Dijon, France. · Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Lyon, France. · Hôpital Cochin, Paris, France. · Centre Hospitalier Universitaire (CHU) de Caen, Centre de Recherche Clinique/Essais de phases précoces, Caen, France. · Gustave Roussy, Translational Research Laboratory, Villejuif, France. · FV Clinical subcontractor for SynteractHCR SAS, Levallois-Perret, France. · Y's therapeutics Inc., Redwood City, CA, USA. · Kissei Pharmaceutical Co., Ltd, Tokyo, Japan. · Department of Rheumatology and Allergy, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. · Division of Hematology/Oncology, University of Florida, Gainesville, FL, USA. · Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan. · Keio University School of Medicine, Tokyo, Japan. · Saitama Medical University, Saitama, Japan. · Y's AC Co., Ltd, Tokyo, Japan. · Pubmed 28291776
2016
  • Department of Pathology, Kyorin University School of Medicine, 6-20-2, Shinkawa, Mitaka-shi, Tokyo, 181-8611, Japan. · Departments of Pathology and Oncology, Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. · Departments of Pathology and Oncology, Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. · Department of Pathology, Tokyo Medical University Hachioji Medical Center, 1163 Tatemachi, Hachioji-shi, Tokyo, 193-0998, Japan. · Therapy Development and Innovation for Immune Disorders and Cancers, Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. · Pubmed 27342200
2014
  • Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Japan. · Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Hongo, Bunkyo-ku, Tokyo, Japan. · Department of Medical Oncology and Clinical Research, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, Yamaguchi, Japan. · Department of Pathology, Keio University school of Medicine, Tokyo, Japan. · Department of Internal Medicine, Okayama Rosai Hospital, Okayama, Japan. · Pubmed 25526639
  • Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. · Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. Electronic address: · Division of Hematology/Oncology, University of Florida, 1600 SW Archer Road, Box 100278, Room MSB M410A, Gainesville, FL 32610, USA. · Department of Pathology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. · Pubmed 24747072
  • Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. · Division of Hematology/Oncology, University of Florida, 1600 SW Archer Road, Box 100278, Room MSB M410A, Gainesville, FL 32610, USA. · Department of Medical Oncology and Clinical Research, National Hospital Organization Yamaguchi-Ube Medical Center, 685 Higashi-Kiwa, Ube, Yamaguchi 755-0241, Japan. · Department of Respiratory Medicine, Okayama Rosai Hospital, 1-10-25 Chikkomidorimachi, Okayama Minami-ku, Okayama 702-8055, Japan. · Department of Pathology, Keio University School of Medicine, 35 Shinanomachi Shinjuku-ku, Tokyo 160-8582, Japan. · Pubmed 24743707
  • Department of Therapy Development and Innovation for Immune disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan ; Division of Clinical Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan. · Department of Therapy Development and Innovation for Immune disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan. · Division of Hematology and Oncology, University of Florida Shands Cancer Center, Gainesville, Florida, United States of America. · Pubmed 24466195
2013
  • Department of Pathology, School of Medicine, Keio University, Shinjuku-ku, Tokyo, Japan. · Pubmed 23638030
2012
  • Division of Clinical Immunology, Institute of Medical Science, University of Tokyo, Japan. · Pubmed 22369943
2011
  • Division of Clinical Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan. · Pubmed 21163253
Juntendo University
2018
  • Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan. · Department of Pathology, Saitama Medical University, Saitama, Japan. · Y's AC Company, Tokyo, Japan. · Biological Research Institute, CA, USA. · Division of Hematology/Oncology, University of Florida Shands Cancer Center, Gainesville, FL, USA. · Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan. Electronic address: · Pubmed 30197002
2017
  • Gustave Roussy, Université Paris-Saclay, Drug Development Department (DITEP), Villejuif, France. · Centre Georges-François Leclerc, Unité de Phases Précoces, Dijon, France. · Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Lyon, France. · Hôpital Cochin, Paris, France. · Centre Hospitalier Universitaire (CHU) de Caen, Centre de Recherche Clinique/Essais de phases précoces, Caen, France. · Gustave Roussy, Translational Research Laboratory, Villejuif, France. · FV Clinical subcontractor for SynteractHCR SAS, Levallois-Perret, France. · Y's therapeutics Inc., Redwood City, CA, USA. · Kissei Pharmaceutical Co., Ltd, Tokyo, Japan. · Department of Rheumatology and Allergy, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. · Division of Hematology/Oncology, University of Florida, Gainesville, FL, USA. · Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan. · Keio University School of Medicine, Tokyo, Japan. · Saitama Medical University, Saitama, Japan. · Y's AC Co., Ltd, Tokyo, Japan. · Pubmed 28291776
2016
  • Dept. of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University. · Pubmed 27431629
  • Department of Pathology, Kyorin University School of Medicine, 6-20-2, Shinkawa, Mitaka-shi, Tokyo, 181-8611, Japan. · Departments of Pathology and Oncology, Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. · Departments of Pathology and Oncology, Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. · Department of Pathology, Tokyo Medical University Hachioji Medical Center, 1163 Tatemachi, Hachioji-shi, Tokyo, 193-0998, Japan. · Therapy Development and Innovation for Immune Disorders and Cancers, Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. · Pubmed 27342200
2014
  • Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Japan. · Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Hongo, Bunkyo-ku, Tokyo, Japan. · Department of Medical Oncology and Clinical Research, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, Yamaguchi, Japan. · Department of Pathology, Keio University school of Medicine, Tokyo, Japan. · Department of Internal Medicine, Okayama Rosai Hospital, Okayama, Japan. · Pubmed 25526639
  • Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. · Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. Electronic address: · Division of Hematology/Oncology, University of Florida, 1600 SW Archer Road, Box 100278, Room MSB M410A, Gainesville, FL 32610, USA. · Department of Pathology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. · Pubmed 24747072
  • Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. · Division of Hematology/Oncology, University of Florida, 1600 SW Archer Road, Box 100278, Room MSB M410A, Gainesville, FL 32610, USA. · Department of Medical Oncology and Clinical Research, National Hospital Organization Yamaguchi-Ube Medical Center, 685 Higashi-Kiwa, Ube, Yamaguchi 755-0241, Japan. · Department of Respiratory Medicine, Okayama Rosai Hospital, 1-10-25 Chikkomidorimachi, Okayama Minami-ku, Okayama 702-8055, Japan. · Department of Pathology, Keio University School of Medicine, 35 Shinanomachi Shinjuku-ku, Tokyo 160-8582, Japan. · Pubmed 24743707
  • Department of Therapy Development and Innovation for Immune disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan ; Division of Clinical Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan. · Department of Therapy Development and Innovation for Immune disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan. · Division of Hematology and Oncology, University of Florida Shands Cancer Center, Gainesville, Florida, United States of America. · Pubmed 24466195
2012
  • Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University. · Pubmed 23259393
3 Other Locations Show
Yearly article counts 011204232010
 
Remember this Person You can save this page -- like a bookmark -- so it's remembered for you on the Expertscape "Saved Pages" page, which is always easily available from the page-top menu bar throughout the site.